HeyJaredBatya Swift Yasgur
- Indexed articles, last 90 days
- 13
- Latest publication
- Oct 1, 2026
- Outlet visibility, for Medscape
- Top 50K sites
- Earliest in this view
- Jul 10, 2026
Latest articles
Obesityâs Epigenetic âMemoryâ Fuels Weight Regain (opens the original)
Read excerpt
Obesity may leave lasting biological changes in adipose tissue that keep levels of the hunger hormone asprosin elevated, potentially contributing to weight regain and increased obesity susceptibility in offspring, new preclinical research suggested. “We found that obesity leaves a lasting ‘memory’ in fat cells that keeps the hunger hormone asprosin turned on, even after weight is lost,” senior author Atul Chopra, MD, PhD, investigator and associate director of the Harrington Rare Disease Program
IBD Onset May Occur Long Before Patients Are Symptomatic (opens the original)
Read excerpt
The onset of inflammatory bowel disease (IBD) may occur long before patients become symptomatic, according to a recent study. Incipient immune signatures of future IBD, silently underway, may be detectable through broad serologic testing as far back as 10 years before diagnosis, offering new insights into the disease’s prodromal phase and a potential path toward earlier identification of high-risk patients. “For practicing clinicians, the main message is that IBD should increasingly be viewed no
Stuttering: New Consensus Statement Highlights Neurobiology (opens the original)
Read excerpt
A new consensus statement issued by an international multidisciplinary panel convened by the Stuttering Treatment and Research Society (STARS) highlights the neurologic aspects of childhood-onset fluency disorder (stuttering), recommending greater physician involvement in diagnosis and management. “This is the first statement to address this commonly misunderstood condition,” Gerald A. Maguire, MD, founder of STARS and lead author of the statement, told Medscape Medical News. Maguire, director o
As GLP-1s Revolutionize Obesity Care, Access Remains Uneven (opens the original)
Read excerpt
GLP-1s have revolutionized the weight-loss landscape, providing effective treatments that can reduce body weight by 15%-25% in patients with obesity within the first year of use. But the GLP-1 era is characterized by a contradiction. Clinicians are witnessing a rapidly expanding population of patients using these medications alongside a substantial number of patients who could potentially benefit but are not receiving them. The reasons underlying this gap are multifactorial, including cost and i
Traditional Chinese Medicines Plus Metformin Improve A1c (opens the original)
Read excerpt
HTD1801, an investigational oral combination of berberine and ursodeoxycholate, significantly reduced A1c when added to metformin in patients with type 2 diabetes (T2D) whose glucose levels remained inadequately controlled with metformin alone, according to results from a phase 3 trial. “For clinicians managing T2D, the key takeaway is that HTD1801 offers a comprehensive approach to patient care,” lead author Linong Ji, MD, of Peking University People’s Hospital, Beijing, China, and senior autho
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 50K sites
For Medscape, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.